WO2022080576A1 - Composition comprenant un inhibiteur de pmca pour le traitement d'une infection à coronavirus ou de maladies infectieuses - Google Patents

Composition comprenant un inhibiteur de pmca pour le traitement d'une infection à coronavirus ou de maladies infectieuses Download PDF

Info

Publication number
WO2022080576A1
WO2022080576A1 PCT/KR2020/016934 KR2020016934W WO2022080576A1 WO 2022080576 A1 WO2022080576 A1 WO 2022080576A1 KR 2020016934 W KR2020016934 W KR 2020016934W WO 2022080576 A1 WO2022080576 A1 WO 2022080576A1
Authority
WO
WIPO (PCT)
Prior art keywords
coronavirus
bat
virus
hcov
cov
Prior art date
Application number
PCT/KR2020/016934
Other languages
English (en)
Korean (ko)
Inventor
김홍렬
졸로마시모
페루시베로니카
Original Assignee
김홍렬
졸로마시모
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김홍렬, 졸로마시모 filed Critical 김홍렬
Publication of WO2022080576A1 publication Critical patent/WO2022080576A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Definitions

  • the present invention relates to a composition for various uses that can effectively ameliorate or treat a coronavirus infection or a disease caused by the infection, including a PMCA inhibitor.
  • Coronavirus is a representative virus that causes lethal infectious diseases in modern civilization.
  • Severe Acute Respiratory Syndrome also known as SARS
  • MERS Middle East Respiratory Syndrome
  • COVID-19 coronavirus
  • SARS Severe acute respiratory syndrome coronavirus 2
  • -CoV-2 Severe acute respiratory syndrome coronavirus 2
  • Coronavirus Infectious Disease-19 is transmitted when droplets (saliva) of an infected person penetrate the respiratory tract or the mucous membranes of the eyes, nose, and mouth. After infection, after an incubation period of about 2 to 14 days (estimated), the main symptoms are fever (37.5 degrees), respiratory symptoms such as cough or shortness of breath, and pneumonia. reach
  • One object of the present invention is to provide a composition for various uses that can improve or treat infection by coronavirus or various diseases caused by the infection.
  • N-(2-(2-butyl-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl) represented by the following formula (1) Ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide (N-(2-(2-butyl-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H) )-yl)ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide) and 4-(imidazo[1,2-b]pyridazin-6-yl) represented by Formula 2 below -N-(3-methoxyphenethyl)piperazine-1-carboxamide(4-(imidazo[1,2-b]pyridazin-6-yl)-N-(3-methoxyphenethyl)piperazine-1-carboxamide ) at least one
  • N- (2- (2-butyl-2,3-dihydrobenzo [f] [1,4] oxazepine-4 (5H) - yl)ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide
  • N-(2-(2-butyl-2,3-dihydrobenzo[f][1,4]oxazepin-4) (5H)-yl)ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide
  • it relates to a method of improving or treating
  • the present invention in principle provides an intermediate, for example in the preparation of a compound according to the invention or a physiologically functional derivative thereof, or a pharmaceutically acceptable salt of a compound according to the invention or a physiologically functional derivative thereof
  • an intermediate for example in the preparation of a compound according to the invention or a physiologically functional derivative thereof, or a pharmaceutically acceptable salt of a compound according to the invention or a physiologically functional derivative thereof
  • salts of the compounds according to the invention which are not themselves pharmaceutically acceptable.
  • Said salts include water-insoluble salts, particularly water-soluble salts.
  • a particular compound according to the invention or a physiologically functional derivative thereof is capable of forming salts, ie whether said compound according to the invention or a physiologically functional derivative thereof is, for example, For example, it can be easily determined whether or not a group has a chargeable group such as an amino group, a carboxylic acid group, and the like.
  • Exemplary salts of the compounds of the present invention are acid addition salts or salts with bases, particularly pharmaceutically acceptable inorganic and organic acid addition salts and salts with bases commonly used in pharmaceuticals, which are water-insoluble or particularly water-soluble acid addition salts. is salt Depending on the substituents of the compounds of the present invention, salts with bases may also be suitable.
  • Acid addition salts can be prepared, for example, by combining a solution of a compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. It can be formed by mixing.
  • pharmaceutically acceptable base addition salts include alkali metal salts (eg, sodium or potassium salts); alkaline earth metal salts (eg, calcium or magnesium salts); and salts formed with suitable organic ligands (eg, ammonium, quaternary ammonium and amines formed with counter anions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyl sulfonates and aryl sulfonates). cations) may be included.
  • alkali metal salts eg, sodium or potassium salts
  • alkaline earth metal salts eg, calcium or magnesium salts
  • suitable organic ligands eg, ammonium, quaternary ammonium and amines formed with counter anions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyl sulfonates and aryl sulfonates
  • Illustrative examples of pharmaceutically acceptable salts include acetate, adipate, alginate, arginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, Bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, ethanesulfonate, Formate, fumarate, galactate, galacturonate, gluconate, glutamate, glycerophosphate, hemisulphate, heptanoate, hexanoate, hexylresorcinate, hydrobromide, hydrochloride, hydroiodide , 2-hydroxy-ethanesulfonate, hydroxynaphthoate
  • Salts which are not pharmaceutically acceptable in the present invention and which, for example, can be obtained as process products during the preparation of the compounds according to the invention on an industrial scale, are also included in the invention and, if desired, are known to the person skilled in the art. It can be converted into a pharmaceutically acceptable salt by a method.
  • the virus may be an RNA virus.
  • the “RNA virus” refers to any virus using RNA as a genetic material.
  • the RNA virus is Coronaviridae, Amalgaviridae, Birnaviridae, Chrysoviridae, Cystoviridae, Endornaviridae ( Endornaviridae), Hypoviridae, Megabirnaviridae, Partitiviridae, Picobirnaviridae, Reoviridae, Totiviridae, Quadriviridae, Arteriviridae, Mesoniviridae, Roniviridae, Dicistroviridae, Iflaviridae, Marnaviridae Marnaviridae, Picornaviridae, Secoviridae, Alphaflexiviridae, Betaflexiviridae, Gammaflexiviridae, Tymoviridae ), Bornaviridae, Filoviridae, Paramyx
  • the "coronavirus (Coronavirus)” has four genera (alpha, beta, gamma, delta) in the coronavirus subfamily (Coronavirinae) of the coronaviridae, and is an RNA virus with a gene size of 27 to 32 kb. It is known to cause respiratory and digestive system infections in animals. It is easily transmitted mainly through mucosal transmission and droplet transmission. Humans usually cause mild respiratory infections, but rarely fatal infections. Diarrhea in cattle and pigs, and respiratory diseases in chickens. Among coronaviruses, coronaviruses that have humans as hosts are divided into classifications in Table 1 below (Centers for Disease Control and Prevention, 2020). Among the four genera, alpha and beta infect humans and animals, and gamma and delta are reported to infect only animals.
  • Virus name Genus host Symptom HCoV-229E Alpha Human mild respiratory symptoms HCoV-NL63 Alpha Human mild respiratory symptoms SARS-CoV Beta Human severe respiratory symptoms MERS-CoV Beta Human severe respiratory symptoms HCoV-OC43 Beta Human mild respiratory symptoms HCoV-HKU1 Beta Human Pneumonia symptoms SARS-CoV-2 Beta Human Mild respiratory symptoms Severe cases can cause shortness of breath
  • beta coronavirus corresponds to a zoonotic infection as one of four genera of coronaviruses in the subfamily Coronavirus.
  • beta coronaviruses include Severe Acute Respiratory Syndrome virus (SARS; SARS-CoV), Severe Acute Respiratory Syndrome virus-2 (SARS-CoV-2), Middle East Respiratory Syndrome virus (SARS-CoV) Middle East Respiratory Syndrome virus (MERS; MERS-CoV), human coronavirus OC43 (HCoV-OC43), or human coronavirus HKU1 (HCoV-HKU1) are known to exist.
  • nucleocapsid protein includes N1, N2 and N3 fragments.
  • the coronavirus includes naturally or artificially mutated variants.
  • the infectious disease caused by the coronavirus is coronavirus enteritis, coronavirus diarrhea, severe acute respiratory syndrome coronavirus (SARS), Middle East respiratory syndrome (MERS), or their It may be a combination, but may be included without limitation as long as it is a disease that can be caused by the coronavirus infection.
  • coronavirus enteritis coronavirus diarrhea
  • severe acute respiratory syndrome coronavirus SARS
  • MERS Middle East respiratory syndrome
  • the infectious disease may be a respiratory disease, hepatitis, gastroenteritis or encephalitis caused by the viral infection.
  • the respiratory disease may be one that causes Severe Acute Respiratory Syndrome (SARS).
  • SARS Severe Acute Respiratory Syndrome
  • the severe acute respiratory syndrome is a disease that can cause infection of the upper or lower respiratory tract, which can cause sudden fever, cough, and shortness of breath, and can progress to pneumonia and even lead to death.
  • composition of the present invention may be used alone or in combination with conventional antiviral agents, or may be used in combination with biological agents such as antiserum.
  • composition of the present invention may be used as a pharmaceutical composition, a food composition, a food additive composition, a feed composition, or a feed additive composition, but is not particularly limited.
  • treatment and “improvement” refer to any action that improves or beneficially changes viral infection by inhibiting virus infection or proliferation by administering the composition of the present invention.
  • the compound or pharmaceutical composition may be characterized in the form of capsules, tablets, granules, injections, ointments, powders or drinks, and the pharmaceutical composition may be characterized in that it is targeted to humans.
  • the pharmaceutical composition of the present invention is not limited thereto, but each can be formulated in the form of oral dosage forms such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injection solutions according to conventional methods.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, colorants, fragrances, etc., in the case of oral administration, and in the case of injections, buffers, preservatives, pain relief A topical agent, solubilizer, isotonic agent, stabilizer, etc.
  • the dosage form of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above.
  • a pharmaceutically acceptable carrier as described above.
  • it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be prepared in the form of unit dose ampoules or multiple doses. there is.
  • it can be formulated as a solution, suspension, tablet, capsule, sustained release formulation, and the like.
  • suitable carriers, excipients and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil may be used.
  • it may further include a filler, an anti-agglomeration agent, a lubricant, a wetting agent, a flavoring agent, an emulsifier, a preservative, and the like.
  • the route of administration of the compound or pharmaceutical composition according to the present invention is, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal , topical, sublingual or rectal. Oral or parenteral administration is preferred.
  • parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.
  • the compound or pharmaceutical composition of the present invention may be determined by several factors including the activity of the specific compound used, age, weight, general health, sex, formula, administration time, administration route, excretion rate, drug formulation, and the severity of the specific disease to be prevented or treated.
  • the dosage of the pharmaceutical composition may vary depending on the patient's condition, body weight, degree of disease, drug form, administration route and period, but may be appropriately selected by those skilled in the art, and from 0.0001 to 0.0001 per day It may be administered at 50 mg/kg or 0.001 to 50 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
  • the pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, and suspensions.
  • the "individual” means a subject who has or is suspected of having a virus infection, and needs improvement or treatment for virus infection or a disease caused by the infection by suppressing virus activity, etc., which is already infected or infected with the virus means any animal, including human beings, who can become
  • a specific pharmaceutically effective amount for a target subject includes the type and extent of the reaction to be achieved, the specific composition comprising the active ingredient, including whether other agents are used in some cases, the age of the patient, Body weight, general health status, sex and diet, administration time, administration route and secretion rate of a composition containing the active ingredient, treatment period, various factors including drugs used or used together with a specific composition and well-known in the pharmaceutical field It is preferable to apply differently depending on similar factors.
  • the amount may be added in a proportion of 0.1 to 50% of the total weight.
  • the food composition is prepared in the form of a beverage, there is no particular limitation other than containing the food composition in the indicated ratio, and it may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage. That is, as natural carbohydrates, monosaccharides such as glucose, disaccharides such as fructose, polysaccharides such as sucrose, and common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol are included. can do.
  • the food composition or food composition additive of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors such as flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
  • These components may be used independently or in combination.
  • the proportion of these additives is not so important, but is generally selected in the range of 0.1 to about 50 parts by weight per 100 parts by weight of the food composition of the present invention.
  • the composition may be 20 to 90% highly concentrated or may be prepared in powder or granular form.
  • the feed additive is an organic acid such as citric acid, humic acid, adipic acid, lactic acid, malic acid, or phosphate such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), polyphenol, catechin, alpha-tocopherol, rosemary Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, any one or more of natural antioxidants such as phytic acid may be further included.
  • organic acid such as citric acid, humic acid, adipic acid, lactic acid, malic acid, or phosphate such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), polyphenol, catechin, alpha-tocopherol, rosemary Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, any one or
  • the composition when the compound represented by Formula 1 or 2 is used as feed, the composition may be formulated in a conventional feed form, and may include common feed ingredients together.
  • the feed additive and feed include grains such as milled or crushed wheat, oats, barley, corn and rice; plant protein feeds, for example feeds based on rape, soybean and sunflower; animal protein feeds such as blood meal, meat meal, bone meal and fish meal; Sugar and dairy products, for example, may further include dry ingredients made of various types of milk powder and whey powder, and in addition, may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like.
  • the compound represented by Formula 1 or 2 when used as the feed additive, it may be administered to an animal alone or in combination with other feed additives in an edible carrier.
  • the feed additives can be easily administered to the animal as a top dressing, directly mixing them into the animal feed, or in an oral formulation separate from the feed.
  • a pharmaceutically acceptable edible carrier as well known in the art to prepare an immediate release or sustained release formulation.
  • Such edible carriers may be solid or liquid, for example corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol.
  • composition provided in the present invention has a coronavirus inhibitory activity, and can effectively improve or treat an infection caused by a coronavirus or a disease caused by the infection.
  • Figure 3 shows the results of confirming the change in the expression level of ACE2 after treating Vero cells with the compound of Formula 2 in Experimental Example 3.
  • N-(2-(2-butyl-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl) represented by the following formula (1) Ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide (N-(2-(2-butyl-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H) )-yl)ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide) and 4-(imidazo[1,2-b]pyridazin-6-yl) represented by Formula 2 below -N-(3-methoxyphenethyl)piperazine-1-carboxamide(4-(imidazo[1,2-b]pyridazin-6-yl)-N-(3-methoxyphenethyl)piperazine-1-carboxamide ) at least one
  • N- (2- (2-butyl-2,3-dihydrobenzo [f] [1,4] oxazepine-4 (5H) - yl)ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide
  • N-(2-(2-butyl-2,3-dihydrobenzo[f][1,4]oxazepin-4) (5H)-yl)ethyl)-3-(2-ethyl-1H-imidazol-1-yl)propanamide
  • it relates to a method of improving or treating
  • RT-25] (IVD approved) kit was used to quantitatively detect N1, N2 and N3 fragments derived from the nucleocapsid (N) gene, which plays an important role in the proliferation of Sars-CoV-2 virus, through real-time RT assay. .
  • the assay was performed at 25° C. for 2 minutes; 15 min at 50 °C; 2 min at 95 °C; 3 seconds at 95 °C; 45 cycles were performed at 55° C. for 30 seconds, and a BioRad CFX96 instrument was used.
  • N1, N2 and N3 obtained by amplifying the RNA sample obtained from the Sars-CoV-2 infected Vero cells pretreated with the compound represented by Formula 2 with the obtained kit were analyzed.
  • the Cq values of these virus targets (N1, N2, N3) were normalized to an internal control (Delta Ct), and the multiples of the virus targets (N1, N2, N3) were calculated for the vehicle CTR-treated cells, and the result was calculated 1 is shown.
  • cells not infected with the Sars-CoV-2 virus and cells treated with the vehicle were used as controls.
  • the assay was performed at 25° C. for 2 minutes; 15 min at 50 °C; 2 min at 95 °C; 3 seconds at 95 °C; 45 cycles were performed at 55° C. for 30 seconds, and a BioRad CFX96 instrument was used.
  • the amplification plots of N1, N2 and N3 obtained by amplifying the RNA sample obtained from the Sars-CoV-2 infected Vero cells pretreated with the compound represented by Formula 2 with the obtained kit were analyzed.
  • the Cq values of these viral targets are shown in Table 3 below, which were normalized to an internal control (Delta Ct), and the viral targets (N1, N2, N3) with respect to vehicle CTR-treated cells Calculate the multiple of , and the results are shown in FIG. 2 . However, cells not infected with the Sars-CoV-2 virus and cells treated with the vehicle were used as controls.
  • Vero cells 5.0 X 10 5 cells were treated with 1 mM of the compound represented by Formula 2 for 15 hours, and the expression level of ACE2 was measured by immunoblot analysis using an anti-ACE antibody (Ab15348) for total protein lysate. did The results are shown in FIG. 3 . However, valproic acid was used as a control here.
  • the present invention relates to a composition for various uses that can effectively ameliorate or treat a coronavirus infection or a disease caused by the infection.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pest Control & Pesticides (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Husbandry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Par l'utilisation du composé représenté par la formule chimique 1 ou 2, la présente invention peut permettre d'atténuer ou de traiter efficacement une infection à coronavirus ou des maladies provoquées par l'infection par l'activité inhibitrice des composés contre le coronavirus.
PCT/KR2020/016934 2020-10-16 2020-11-26 Composition comprenant un inhibiteur de pmca pour le traitement d'une infection à coronavirus ou de maladies infectieuses WO2022080576A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200134123A KR102590444B1 (ko) 2020-10-16 2020-10-16 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
KR10-2020-0134123 2020-10-16

Publications (1)

Publication Number Publication Date
WO2022080576A1 true WO2022080576A1 (fr) 2022-04-21

Family

ID=81208234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/016934 WO2022080576A1 (fr) 2020-10-16 2020-11-26 Composition comprenant un inhibiteur de pmca pour le traitement d'une infection à coronavirus ou de maladies infectieuses

Country Status (2)

Country Link
KR (1) KR102590444B1 (fr)
WO (1) WO2022080576A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039714A2 (fr) * 2012-09-06 2014-03-13 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
KR20140138865A (ko) * 2012-03-09 2014-12-04 렉시컨 파마슈티컬스 인코퍼레이티드 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
JP2015513557A (ja) * 2012-03-09 2015-05-14 レクシコン ファーマシューティカルズ インコーポレイテッド 疼痛の治療に対するアダプター関連キナーゼ１の阻害
KR20170009276A (ko) * 2015-07-16 2017-01-25 일양약품주식회사 호흡기 바이러스성 질환 치료를 위한 라도티닙의 용도
KR20180018683A (ko) * 2015-06-15 2018-02-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102260675B1 (ko) * 2019-07-30 2021-06-07 주식회사 하임바이오 신규한 항암용 화합물, 및 이를 유효성분으로 포함하는 약학조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138865A (ko) * 2012-03-09 2014-12-04 렉시컨 파마슈티컬스 인코퍼레이티드 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
JP2015513557A (ja) * 2012-03-09 2015-05-14 レクシコン ファーマシューティカルズ インコーポレイテッド 疼痛の治療に対するアダプター関連キナーゼ１の阻害
WO2014039714A2 (fr) * 2012-09-06 2014-03-13 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
KR20180018683A (ko) * 2015-06-15 2018-02-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
KR20170009276A (ko) * 2015-07-16 2017-01-25 일양약품주식회사 호흡기 바이러스성 질환 치료를 위한 라도티닙의 용도

Also Published As

Publication number Publication date
KR20220050435A (ko) 2022-04-25
KR102590444B1 (ko) 2023-10-18

Similar Documents

Publication Publication Date Title
KR101706624B1 (ko) 고병원성 감염성 질환의 예방 및 치료제
KR101658048B1 (ko) 포스파티딜콜린 합성경로 관여 물질을 포함하는 항바이러스용 조성물
WO2016159582A2 (fr) Composition destinée à renforcer l'immunité innée et l'activité antivirale contenant un extrait de schizonepeta tenuifolia à titre de principe actif
WO2022080576A1 (fr) Composition comprenant un inhibiteur de pmca pour le traitement d'une infection à coronavirus ou de maladies infectieuses
KR102597757B1 (ko) 천연물 유래 화합물 및 이를 유효성분으로 함유하는 항바이러스제
KR102573565B1 (ko) 플라보노이드 계열 화합물 및 이를 유효성분으로 함유하는 항바이러스제
WO2022080577A1 (fr) Composition comprenant un inhibiteur de pmca pour la prévention d'une infection à coronavirus ou de maladies infectieuses ou pour la désinfection
US20230114000A1 (en) Antiviral composition containing fucosyllactose as active ingredient
WO2022149929A1 (fr) Composition pharmaceutique antivirale comprenant un inhibiteur de stéroïde sulfatase
KR20240018822A (ko) 고시폴을 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 치료용 조성물
WO2023121362A1 (fr) Composition antivirale comprenant des analogues nucléosidiques dérivés d'un acide nucléique et d'un sel pharmaceutiquement acceptable de celui-ci
KR20220134489A (ko) 폴리포스페이트를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
WO2022014813A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une infection par le sars-cov-2
WO2021215617A1 (fr) Composition pour la désinfection ou la prévention d'une infection par un coronavirus, ou de maladies infectieuses provoquées par celui-ci, comprenant un polyphosphate
KR102641463B1 (ko) 바이러스 감염질환의 예방 또는 치료를 위한 화합물, 이를 포함하는 조성물 및 이의 용도
CN116847862A (zh) 甘蔗提取物在治疗或预防微生物感染和生态失调中的用途
WO2023085664A1 (fr) Composition contenant de l'acide taurodésoxycholique ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif pour la prévention ou le traitement de maladies infectieuses virales
KR102572694B1 (ko) 베네토클락스 및 렘데시비르를 유효성분으로 하는 코로나-19 감염증 예방 또는 치료용 약학 조성물
WO2020235900A1 (fr) Utilisation d'une composition pour la prévention, l'amélioration ou le traitement de troubles de la perte osseuse, comprenant le cyclo-hispro (chp) et l'hormone parathyroïde
WO2022250385A1 (fr) Composition contenant un dérivé de macrolactine ou un sel de qualité pharmaceutique de celui-ci en tant que principe actif pour la prévention ou le traitement d'une maladie infectieuse causée par le virus de la fièvre aphteuse
WO2022131604A1 (fr) Composition antivirale contenant un composé dérivé de ramulus mori en tant que principe actif
WO2024144320A1 (fr) Composition antivirale comprenant des analogues nucléosidiques dérivés d'acide nucléique et sels pharmaceutiquement acceptables de ceux-ci
KR101825090B1 (ko) 리바비린 또는 그 유도체를 포함하는 구제역 치료용 조성물
WO2017171112A1 (fr) Composition améliorant l'immunité innée et antivirale contenant un extrait d'anethum graveolens en tant que substance active
KR20210116153A (ko) 레비스틸라이드 a를 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20957820

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20957820

Country of ref document: EP

Kind code of ref document: A1